Lestaurtinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Lestaurtinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Lestaurtinib can convert its Small molecule drug profile and FLT3 x JAK2 x TrkA x TrkB x TrkC biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Lestaurtinib (query alias: Lestaurtinib) |
|---|---|
| Modality / target | Small molecule drug; FLT3 x JAK2 x TrkA x TrkB x TrkC; FLT3 inhibitors, JAK2 inhibitors, TrkA antagonists |
| Highest global status | Phase 3 |
| Originator | Kyowa Kirin Co., Ltd. |
| Active developers | Kyowa Kirin Co., Ltd., Cephalon LLC |
The MCP disease footprint includes Acute Lymphoblastic Leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| EUCTR2005-005542-39-DE | Phase 2 | Completed | 100 | Safety and tolerability will be assessed by evaluating: - incidence, intensity, and attribution of treatment-emergent adverse events - serum chemistry, haematology, and urine laboratory values - vital signs and physical examinations - the administration of concomitant medications Objective disease progression as determined by routine haematology. |
| EUCTR2008-002317-40-DE | Phase 2 | Completed | 80 | Change from baseline in local PASI |
| NCT00586651 | Phase 2 | Completed | 39 | Determine whether a specific reduction in the JAK2 V617F allele has been indicated in this study. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis
Phase 1; n=34; evaluation: Positive. Reported fields: clinical improvement(12-week) = 43.8 %
A Pilot Study of Lestaurtinib (CEP-701) in Combination With Chemotherapy in Young Patients With Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia
Phase 1/2; n=14; evaluation: not stated. Reported fields: DLT = 0 participants ; DLT = 0 participants ; -
Evaluation of CEP-701, an Orally Available JAK2 Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis
Phase 2; n=27; evaluation: not stated. Reported fields: CR = 0 Participants ; -; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Lestaurtinib addresses Acute Lymphoblastic Leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 57 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: FLT3 x JAK2 x TrkA x TrkB x TrkC records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-07-15 | An undisclosed company to acquire Senti's Gene-Circuit-enabled pipeline assets for AML, other blood cancers and solid tumors | Phase 1 | US$60.0M stated total |
| 2026-05-14 | Aptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks development | Phase 1 | Financial terms not disclosed |
| 2026-05-14 | Allogene Therapeutics ends China cell therapy deal with Overland | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
